DnB Asset Management
XENE icon

DnB Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

DnB Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Buy
200,451
+19,366
+11% +$1.08M 0.03% 318
2026
Q1 		$10.5M Sell
181,085
-91,746
-34% -$4.23M 0.04% 296
2025
Q4 		$12.2M Buy
272,831
+23,750
+10% +$997K 0.04% 256
2025
Q3 		$10M Buy
249,081
+14,924
+6% +$526K 0.04% 299
2025
Q2 		$7.33M Buy
234,157
+4,675
+2% +$152K 0.03% 317
2025
Q1 		$7.7M Buy
229,482
+26,239
+13% +$996K 0.04% 302
2024
Q4 		$7.97M Buy
203,243
+12,620
+7% +$522K 0.03% 305
2024
Q3 		$7.5M Buy
190,623
+14,890
+8% +$600K 0.03% 313
2024
Q2 		$6.85M Buy
175,733
+49,483
+39% +$1.98M 0.03% 296
2024
Q1 		$5.44M Sell
126,250
-125
-0.1% -$5.75K 0.03% 341
2023
Q4 		$5.82M Buy
126,375
+4,605
+4% +$163K 0.03% 330
2023
Q3 		$4.16M Buy
121,770
+9,141
+8% +$342K 0.02% 385
2023
Q2 		$4.34M Buy
112,629
+13,770
+14% +$547K 0.02% 382
2023
Q1 		$3.54M Buy
98,859
+4,308
+5% +$159K 0.02% 435
2022
Q4 		$3.73M Buy
+94,551
New +$3.44M 0.03% 407

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

DnB Asset Management's XENE Position: Q2 2026 in Review

DnB Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 11% in Q2 2026, buying an estimated $1.08M and bringing the position to 200,451 shares worth $12.1M. The position accounts for 0.03% of the portfolio, ranked #318.

DnB Asset Management first reported a position in XENE in Q4 2022 and has held it in 15 quarters since. The position peaked at $12.2M in Q4 2025. 124 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • DnB Asset Management held 200,451 shares of Xenon Pharmaceuticals worth $12.1M as of Q2 2026.
  • DnB Asset Management bought 19,366 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Xenon Pharmaceuticals made up 0.03% of DnB Asset Management's portfolio in Q2 2026, its #318 holding.
  • DnB Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • DnB Asset Management's Xenon Pharmaceuticals position peaked at $12.2M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.